The Convalescent Serum for Treatment of COVID-19 Infection: Review

Sadeq Kadhim Hachim

doi:10.30935/ejmets/8016

EUROPEAN JOURNAL OF MEDICAL AND EDUCATIONAL TECHNOLOGIES

The Convalescent Serum for Treatment of COVID-19 Infection: Review

Sadeq Kadhim Hachim ¹ ^*

More Detail

EUROPEAN J MED ED TE, Volume 13, Issue 1, Article No: em2005

https://doi.org/10.30935/ejmets/8016

OPEN ACCESS 555 Views 379 Downloads

Download Full Text (PDF)

Abstract

In the early of 2020, people are challenging a pandemic in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 causes coronavirus disease, abbreviated as COVID-19. At the time of this writing, SARS-CoV-2 is spreading in multiple countries worldwide. There are above two million cases in different region of world. This virus appears to be a new human pathogen. Currently there are no vaccines, monoclonal antibodies (mAbs), or drugs available for SARS-CoV-2, though many are in rapid development and some may be accessible in a short time. This aim of this review that human convalescent serum is an option for stoppage and treatment of COVID-19 disease. Explain main advantage of convalescent serum, in addition to disadvantage of this method.

Keywords: COVID-19, convalescent serum, treatment, antibody

References

Zhou P, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579: 270-3.
Chen N, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020; 395: 507-13.
World Health Organization, Coronavirus disease (COVID-19) Pandemic. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019 (Accessed 11 March 2020).
Mair-Jenkins J, et al. Convalescent Plasma Study Group, The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory metanalysis. J. Infect. Dis 2015; 211: 80-90.
van Griensven J, et al. Ebola-Tx Consortium, Evaluation of convalescent plasma for Ebola virus disease in Guinea. N. Engl. Med. 2016; 347: 33-42.
Lee PI, Hsueh PR. Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCOV. J. Micrbio. Immunol. Infect., in press 2020.
Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect. Dis. 2020; 20: 398-400.
Shen C, Wang Z, Zhao F, et al. Treatment of 5 Critically Ill Patients WithCOVID-19 With Convalescent Plasma. American Medical association; March27: 2020.
Cheng Y, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005; 24(1): 44-6.
Yeh KM, et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother. 2005; 56(5): 919-22.
Ko JH, et al. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antivir Ther (Lond). 2018; 23(7): 617-22.
Arabi YM, et al. Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerging Infect Dis. 2016; 22(9): 1554-61.
Zhang JS, et al. A serological survey on neutralizing antibody titer of SARS convalescent sera. J Med Virol. 2005; 77(2): 147-50.
van Erp EA, Luytjes W, Ferwerda G, van Kasteren PB. Fc-mediated antibody effector functions during respiratory syncytial virus infection and disease. Front Immunol. 2019; 10: 548.
Jenks JA, Goodwin ML, Permar SR. The roles of host and viral antibody fc receptors in herpes simplex virus (HSV) and human cytomegalovirus (HCMV) infections and immunity. Front Immunol. 2019; 10: 2110.
Gunn BM, et al. A role for Fc function in therapeutic monoclonal antibody-mediated protection against ebola virus. Cell Host Microbe. 2018; 24(2): 221–233.e5.
Duana K, Liuc B, Lid C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19. PNAS 2020: 1-7.
Casadevall A, Pirofski L-A. The convalescent sera option for containing COVID-19. J Clin Invest. 2020; 130(4): 1545-8.
Luke TC, Casadevall A, Watowich SJ, Hoffman SL, Beigel JH, Burgess TH. Hark back: passive immunotherapy for influenza and other serious infections. Crit Care Med. 2010; 38(4 suppl): e66-e73.

Citation

Hachim SK. The Convalescent Serum for Treatment of COVID-19 Infection: Review. EUROPEAN J MED ED TE. 2020;13(1):em2005. https://doi.org/10.30935/ejmets/8016

Hachim, S. K. (2020). The Convalescent Serum for Treatment of COVID-19 Infection: Review. European Journal of Medical and Educational Technologies, 13(1), em2005. https://doi.org/10.30935/ejmets/8016

Hachim, S. K. (2020). The Convalescent Serum for Treatment of COVID-19 Infection: Review. European Journal of Medical and Educational Technologies, 13(1), em2005. https://doi.org/10.30935/ejmets/8016

Hachim SK. The Convalescent Serum for Treatment of COVID-19 Infection: Review. EUROPEAN J MED ED TE. 2020;13(1), em2005. https://doi.org/10.30935/ejmets/8016

Hachim, Sadeq Kadhim. "The Convalescent Serum for Treatment of COVID-19 Infection: Review". European Journal of Medical and Educational Technologies 2020 13 no. 1 (2020): em2005. https://doi.org/10.30935/ejmets/8016

Hachim, Sadeq Kadhim "The Convalescent Serum for Treatment of COVID-19 Infection: Review". European Journal of Medical and Educational Technologies, vol. 13, no. 1, 2020, em2005. https://doi.org/10.30935/ejmets/8016